230 related articles for article (PubMed ID: 35941565)
1. Impact of adjuvant chemotherapy on T1N0M0 breast cancer patients: a propensity score matching study based on SEER database and external cohort.
Shen K; Yao L; Zhu J; Gu X; Wang J; Qian W; Zheng Z; Fu D; Wu S
BMC Cancer; 2022 Aug; 22(1):863. PubMed ID: 35941565
[TBL] [Abstract][Full Text] [Related]
2. Would 1.0 cm be a more suitable cutoff to subdivide pT1 tumors in hormone receptor-negative and HER2-positive breast cancer?
Wang C; Zhou Y; Zhu H; Huang W; Chen Z; Mao F; Lin Y; Zhang X; Shen S; Zhong Y; Li Y; Sun Q
Cancer Med; 2018 Nov; 7(11):5420-5430. PubMed ID: 30277006
[TBL] [Abstract][Full Text] [Related]
3. [Effects of adjuvant trastuzumab on long-term survival of T1N0M0 stage human epidermal growth factor receptor 2 positive breast cancer: a real-world study].
Sun TH; Lu ZN; Song HT; Sun G
Zhonghua Zhong Liu Za Zhi; 2023 Jan; 45(1):101-107. PubMed ID: 36709127
[No Abstract] [Full Text] [Related]
4. Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database.
Hu G; Hu G; Zhang C; Lin X; Shan M; Yu Y; Lu Y; Niu R; Ye H; Wang C; Xu C
BMC Cancer; 2020 Feb; 20(1):136. PubMed ID: 32085753
[TBL] [Abstract][Full Text] [Related]
5. Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer.
Nguyen TTA; Postlewait LM; Zhang C; Meisel JL; O'Regan R; Badve S; Kalinsky K; Li X
Breast Cancer Res Treat; 2022 Apr; 192(3):509-516. PubMed ID: 35084624
[TBL] [Abstract][Full Text] [Related]
6. The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
van Ramshorst MS; van der Heiden-van der Loo M; Dackus GM; Linn SC; Sonke GS
Breast Cancer Res Treat; 2016 Jul; 158(2):361-71. PubMed ID: 27357813
[TBL] [Abstract][Full Text] [Related]
7. Effect of adjuvant chemotherapy in patients with ER + /HER2- breast cancer, assessed by propensity score matching: significance of nuclear grade and nodal status.
Tanaka N; Hirano A; Hattori A; Ogura K; Kamimura M; Inoue H; Yukawa H; Sakaguchi S; Matsuoka A; Kodera A; Shimizu T
Breast Cancer; 2021 Jan; 28(1):40-47. PubMed ID: 32592141
[TBL] [Abstract][Full Text] [Related]
8. Tumor size is associated with adjuvant chemotherapy benefit in T1N0M0 triple-negative breast cancer: a multicenter and propensity score matched analysis.
Wu C; Huang O; Wu J; Shen K; Chen X; Zhu S
Gland Surg; 2023 Oct; 12(10):1375-1386. PubMed ID: 38021197
[TBL] [Abstract][Full Text] [Related]
9. Benefit of adjuvant chemotherapy in lymph node-negative, T1b and T1c triple-negative breast cancer.
Carbajal-Ochoa W; Bravo-Solarte DC; Bernal AM; Anampa JD
Breast Cancer Res Treat; 2024 Jan; 203(2):257-269. PubMed ID: 37833449
[TBL] [Abstract][Full Text] [Related]
10. A US Registry-Based Assessment of Use and Impact of Chemotherapy in Stage I HER2-Positive Breast Cancer.
Parsons BM; Uprety D; Smith AL; Borgert AJ; Dietrich LL
J Natl Compr Canc Netw; 2018 Nov; 16(11):1311-1320. PubMed ID: 30442732
[No Abstract] [Full Text] [Related]
11. T1a triple negative breast cancer has the worst prognosis among all the small tumor (<1 cm) of TNBC and HER2-rich subtypes.
Wang C; Chen Z; Zhou Y; Huang W; Zhu H; Mao F; Lin Y; Zhang Y; Guan J; Cao X; Sun Q
Gland Surg; 2021 Mar; 10(3):943-952. PubMed ID: 33842238
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy use and surgical treatment by receptor subtype in node-negative T1a and T1b female breast cancers, Iowa SEER Registry, 2010 to 2012.
Schroeder MC; Lynch CF; Abu-Hejleh T; Chrischilles EA; Thomas A
Clin Breast Cancer; 2015 Feb; 15(1):e27-34. PubMed ID: 25245424
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy could benefit early-stage ER/PR positive mucinous breast cancer: A SEER-based analysis.
Gao HF; Li WP; Zhu T; Yang CQ; Yang M; Zhang LL; Ji F; Cheng MY; Li JQ; Wang K
Breast; 2020 Dec; 54():79-87. PubMed ID: 32947149
[TBL] [Abstract][Full Text] [Related]
14. Characteristics and clinical outcome of T1 breast cancer: a multicenter retrospective cohort study.
Houvenaeghel G; Goncalves A; Classe JM; Garbay JR; Giard S; Charytensky H; Cohen M; Belichard C; Faure C; Uzan S; Hudry D; Azuar P; Villet R; Gimbergues P; Tunon de Lara C; Martino M; Lambaudie E; Coutant C; Dravet F; Chauvet MP; Chéreau Ewald E; Penault-Llorca F; Esterni B
Ann Oncol; 2014 Mar; 25(3):623-628. PubMed ID: 24399079
[TBL] [Abstract][Full Text] [Related]
15. Survival Outcome and Impact of Chemotherapy in T1 Node-Negative Triple-Negative Breast Cancer: A SEER Database Analysis.
Zhang J; Wang W; Wang J; Luo Y; Chen S; Ma F; Xu B; Fan Y
J Oncol; 2020; 2020():8880727. PubMed ID: 33381180
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant chemotherapy and survival outcomes in older women with HR+/HER2- breast cancer: a propensity score-matched retrospective cohort study using the SEER database.
Ma X; Wu S; Zhang X; Chen N; Yang C; Yang C; Cao M; Du K; Liu Y
BMJ Open; 2024 Mar; 14(3):e078782. PubMed ID: 38490656
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy for small, lymph node-negative, triple-negative breast cancer: A single-center study and a meta-analysis of the published literature.
An X; Lei X; Huang R; Luo R; Li H; Xu F; Yuan Z; Wang S; de Nonneville A; Gonçalves A; Houvenaeghel G; Li J; Xue C; Shi Y
Cancer; 2020 Aug; 126 Suppl 16():3837-3846. PubMed ID: 32710666
[TBL] [Abstract][Full Text] [Related]
18. The Effect of Adjuvant Treatment in Small Node-negative HER2-positive Breast Cancer: Which Subgroup Will Benefit?
Lin H; Zheng H; Ge C; Wang Q; Tang W; Zhang X; Zhou S; Jin X; Xu X; Du J; Fu J
Clin Breast Cancer; 2020 Dec; 20(6):503-510. PubMed ID: 32653474
[TBL] [Abstract][Full Text] [Related]
19. Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system.
Fehrenbacher L; Capra AM; Quesenberry CP; Fulton R; Shiraz P; Habel LA
J Clin Oncol; 2014 Jul; 32(20):2151-8. PubMed ID: 24888815
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant chemotherapy in patients with ER-negative/HER2-negative, T1abN0 breast cancer: a nationwide study.
Hassing CMS; Mejdahl MK; Lænkholm AV; Kroman N; Knoop AS; Tvedskov THF
Breast Cancer Res Treat; 2023 Feb; 198(1):103-112. PubMed ID: 36576678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
